Regulatory-affairs lead must resolve whether to drop a secondary endpoint

Situation

A mid-size sponsor after a complete response letter cannot treat a DSMB note on an imbalance that is not yet a signal as color commentary on RWE protocol that may not meet regulator expectations. Regulatory-affairs lead must close to drop a secondary from that extract under Pharma & Life Sciences / FDA Response and Labeling.

Decision

Regulatory-affairs lead in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after a DSMB note on an imbalance that is not yet a signal.

Hypotheses to test

• RWE protocol that may not meet regulator expectations reads as Proceed under protocol once a DSMB note on an imbalance that is not yet a signal is lined up to the same Pharma & Life Sciences population.
• RWE protocol that may not meet regulator expectations is closer to Pause the pathway after a DSMB note on an imbalance that is not yet a signal; Proceed under protocol would over-claim this FDA Response and Labeling extract.
• Escalate safety review is still live in RWE protocol that may not meet regulator expectations for regulatory-affairs lead in a mid-size sponsor after a complete response letter.
• RWE protocol that may not meet regulator expectations is missing the fact regulatory-affairs lead needs after a DSMB note on an imbalance that is not yet a signal; stop this Pharma & Life Sciences close.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after a DSMB note on an imbalance that is not yet a signal.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary.
• For this Pharma & Life Sciences FDA Response and Labeling file, read RWE protocol that may not meet regulator expectations against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move to drop a secondary for regulatory-affairs lead.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (RWE protocol that may not meet regulator expectations after a DSMB note on an imbalance that is not yet a signal). If RWE protocol that may not meet regulator expectations cannot force a Pharma & Life Sciences label under FDA Response and Labeling, stop. Do not invent pages a mid-size sponsor after a complete response letter does not have.